Procaps Group conducts its business through its subsidiary, Crynssen Pharma Group Limited (Procaps), an integrated international healthcare and pharmaceutical company that has capabilities in developing and manufacturing Softgel capsules and related dosage forms as evidenced by its development of various pharmaceutical products formulations. Co.'s operating segments including: NextGel, Procaps Colombia, Central America North ("CAN"), Central America South & North Andes ("CASAN") - manufacturing and distribution of prescription and over-the-counter pharmaceutical products; and diabetrics, diabetes solutions and chronic disease management tool. We show 1 historical shares outstanding datapoints in our PROC shares outstanding history coverage, used to compute PROC market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing PROC market cap history over the course of time is important for investors
interested in comparing PROC's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of PROC versus a peer is one thing; comparing
PROC market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like PROC can fluctuate over the course of history.
With this page we aim to empower investors researching PROC by allowing them to research the PROC market cap history. |
Free PROC Email Alerts:
Video: The Importance of Market Cap
